Patient-derived Xenograft (PDX) Mouse Models
Recapitulate the tumor and patient heterogeneity and response to treatment using patient-derived xenograft (PDX) mouse models
InnoSer’s Patient-derived Xenograft (PDX) Mouse Models Services
Patient-derived xenograft (PDX) mouse models are established from resected tumor samples obtained from oncologic patients that are implanted and grown in immunodeficient mice. However, to fully recapitulate the intricacies between the immune system and the tumor microenvironment, humanized mouse models are recommended instead of immunodeficient mice. Patient-derived xenograft (PDX) mouse models represent the most clinically relevant and predictive tool in your drug development journey, recapitulating the tumor and patient heterogeneity, gene expression, and response to treatment.
Therefore, experts from InnoSer’s immuno-oncology team recommend the use of PDX mouse models whenever you have carried out initial in vivo studies using cell line-derived (CDX) mouse models and wish to obtain more clinically relevant results. Accordingly, patient-derived xenografts are suitable for evaluating a range of therapies ranging from immunotherapy, antibody, antibody-drug conjugate, and gene therapies to small molecules (cytotoxic drugs). PDX models provide you with a highly predictive in vivo model for therapeutic efficacy evaluation.
Compared to other preclinical in vivo models, patient-derived xenograft models represent more robust models, requiring longer study timelines and the inclusion of different patient samples to capture your compound’s efficacy on patient heterogeneity.
✓ Well-characterised parental samples (histopathology, hot spot analyses, mutational burden, treatment history, response to treatment).
✓ Complementary in vitro assays using patient-derived organoids (tumoroids).
✓ On-request PDX expansion services.

Developing new, safe, and efficacious anticancer therapies is an extremely intricate process. As a preclinical oncology contract research organization (CRO), InnoSer partners with you to help you navigate the complexities of this research area.
Scientists at InnoSer collaborate with you to develop the most optimal study design to help answer your research questions most cost-effectively. With flexible and fast study start times you can perform your research at an accelerated pace. By outsourcing your preclinical oncology studies to InnoSer, you gain access to our in vitro and in vivo oncology drug development portfolio.
Unlock the Right Tools for Your Research.
Let our team help you navigate InnoSer’s extensive biobank to find patient samples of interest, including detailed data on hotspot mutations, tumor growth curves, and treatment responses.

Patient-derived Xenograft (PDX) Mouse Models Sample Data

Example tumor growth of PDAC PDX from InnoSer’s Biobank. Tumor growth curves of InnoSer’s PDX of pancreatic ductal adenocarcinoma sample sc. implanted into female SCID mice.
Example tumor growth of PDAC PDX from InnoSer’s Biobank. Tumor growth curves of InnoSer’s PDX of pancreatic ductal adenocarcinoma (PDAC; V-INNO-016) sample sc. implanted into female SCID mice. This model offers a compelling genetic profile with KRAS (KRAS mutations are present in over 90% of PDAC cases) and JAK2 mutations. For a detailed overview, reach out to our team and obtain the full tumor sample profile including patient information, parental genomics and DNA HotSpot mutations, histopathology, and RNAseq data here.

Histopathology images from a PDX sample of mucinous pancreatic adenocarcinoma, stained for the cancer marker MUC5AC.

Histopathology images from a PDX sample of non-keratinizing squamous lung carcinoma showing p63 expression.
Key Patient-derived Xenograft (PDX) Mouse Models Readouts
The People Behind Your Research
Céline Erens, PhD, Immunology Study Director
An expert team led by our immuno-oncology study director, Céline Erens helps you choose the right tools and set up optimal study designs. Curating the preclinical testing of your lead compounds with a deep understanding of the field is your solution to accelerating your drug development.
Yanick Fanton, PhD, Chief Scientific Officer
As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.
Oncology Board Members
Prof. Dr. Esther Wolfs
A member of InnoSer’s Scientific Advisory Board, Dr. Wolfs is a leading researcher in stem cell therapy. Currently a professor at the University of Hasselt, Ester uses stem cells in anticancer therapy and as a model to study Charcot-Marie-Tooth disease type 1A.
MD, PhD Marije Slingerland
A member of InnoSer’s Scientific Advisory Board, Dr. Slingerland from Leiden University Medical Center focuses on clinical trials in gastrointestinal cancer and in head and neck cancer, particularly on intratumoral immune parameters.
Discover Other Related Oncology Research Models
Stay Curious: More Articles to Explore
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com